Kornimate/medical-research-clean huggingface dataset:
clinical effect of panfoxol of otolaryngological diseases of upper respiratory tract infection: a multicenter retrospective observational study

Conditions: Otologic Disease

Summary: patients with otolaryngological diseases caused by upper respiratory tract infections, including allergic rhinitis, chronic rhinosinusitis, secretory otitis media, and oblate gland hypertrophy, were treated with all drugs from sun yat-sen memorial hospital of sun yat-sen university, the first affiliated hospital of sun yat-sen university, guangdong provincial people's hospital, and guangdong provincial hospital of traditional chinese medicine from january 2021 to december 2022. according to the treatment methods, the patients were divided into panfosol + conventional treatment group and conventional treatment group for multicenter retrospective analysis.

firstly, data of all patients were collected before and after treatment, including nasal endoscopy lund kennedy score, vas scale for nasal/facial/olfactory symptoms, and ear/nose/snoring vas scale, etc. according to the change values before and after treatment, the treatment results were divided into cure (complete control of the disease), effective (partial control of the disease), ineffective (uncontrolled disease). secondly, all participants were reviewed for gastrointestinal disturbances (nausea, abdominal pain, vomiting), skin reactions (rash, urticaria), respiratory discomfort (cough, dyspnea, asthma), and common problems (fever, fatigue, allergic reactions) after medication.

Eligibility criteria:
inclusion criteria: 1. those who were diagnosed as ear, nose and throat diseases caused by upper respiratory tract infection, such as allergic rhinitis, chronic rhinosinusitis, secretory otitis media, and oblate gland hypertrophy 2. complete clinical data were available at least once both before and after treatment exclusion criteria: 1. patients who are allergic to the ingredient panfosol 2. autoimmune disease 3. acute intestinal infection 4. children younger than 1 year old 5. patients diagnosed with nasopharyngeal carcinoma and other space-occupying diseases by imaging examination 6. basic information is incomplete

Keywords: panfoxol otologic disease curative effect upper respiratory tract infection (urti)
immediate versus delayed induction in term-prom using or not antibiotic prophylaxis

Conditions: Maternal Infection During Pregnancy (Diagnosis); Neonatal Infection

Summary: the primary aim of this study is to determine if antibiotics combined with immediate induction can significantly reduce the rate of maternal and neonatal infection compared with immediate induction alone in women presenting with prom later than the 37+0 weeks of gestation. the secondary aim is to compare the rates of infection between immediate and delayed induction in women submitted to antibiotic prophylaxis.

in a randomized controlled non-blind trial, low-risk women with singleton term pregnancies and a negative group b streptococcus culture presenting with prom are randomly assigned to group a (immediate induction with antibiotic prophylaxis), group b (immediate induction without antibiotic prophylaxis) or group c (delayed induction with antibiotic prophylaxis).

Eligibility criteria:
inclusion criteria: * term (≥ 37+0 weeks) singleton pregnancy, a vertex presentation, ruptured membranes for less than 12 hours and a negative group b streptococcus (gbs) culture performed between 35 and 37 weeks. exclusion criteria: * active labor, absence of gbs culture or indication for gbs antibiotic prophylaxis, contraindication to expectant management or to vaginal delivery

Keywords: term premature rupture of membranes, antibiotic prophylaxis, chorioamnionitis, endometritis, neonatal infection
randomized study comparing two models of a travoprost intraocular implant to timolol maleate ophthalmic solution, 0.5%

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: phase iii study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus timolol maleate ophthalmic solution, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (oag) or ocular hypertension (oht).

this is a prospective, randomized, double-masked, active-controlled, parallel-group, multi-center trial comparing the efficacy and safety of the model g2tr 063 travoprost intraocular implant and the model g2tr-125 travoprost intraocular implant to topical timolol in subjects with oag or oht. the staff who record key efficacy measures and the study subjects will remain masked to study treatment.

Eligibility criteria:
inclusion criteria: * diagnosed with open-angle glaucoma or ocular hypertension. * c/d ratio ≤ 0.8 * zero to three preoperative ocular hypotensive medications exclusion criteria: * active corneal inflammation or edema. * retinal disorders not associated with glaucoma.
music intervention in the treatment of sleep disorders for depressed patients

Conditions: Insomnia; Depression

Summary: the purpose of this study is to determine whether music hearing in the evening before going to sleep can improve sleep quality, depressive symptoms and quality of life in patients with affective disorders.

disrupted sleep including problems of initiating and maintaining sleep are most often symptoms in patients with depressive syndromes and often persist after successful treatment of affective symptoms. normally disrupted sleep in the context of affective disorder is treated with sleep medication, which can lead to severe and sometimes intolerable side effects. a non-pharmacological approach for improving sleep quality is hearing music before going to sleep. classical indian music can improve sleep quality in depressed patients. in a danish study protocol western music improved sleep quality in patients with disturbed sleep and posttraumatic stress disorder. the investigators want to use western music to improve sleep . in a three week intervention time, patients shall hear before going to sleep every night for one hour relaxing music. the control group receives treatment as usual. after the end of intervention, every participant has the possibility to use the sleep inducing music. the aim of the study is to prove whether hearing music before going to sleep over three weeks improves subjective sleep quality, self rated depressive symptoms and quality of life and objective parameters such as sleep duration and sleep latency, measured by actigraphy. in a follow-up interview four weeks after the intervention the investigators want to prove if the effects continue after end of intervention.

Eligibility criteria:
inclusion criteria: * inpatient and outpatient treatment in sanatorium kilchberg * one of the following diagnoses according to icd 10: f32, f33, f34.1, f34.21, f34.8, * age between 18 and 65 years * completed primary education level * good command of the german language * able to understand patient information, * given informed consent, exclusion criteria: * no informed consent * one or more of the following diagnoses according to icd 10: f32.3, f33.2, f31.3, f31.4, f60.31, f10, f13, f00, f01, f02, f03, g47.3, g25.8, h90, h91 * patients with acute suicidal tendency * pregnant or breastfeeding women

Keywords: sleep quality depression music quality of life
barrier function and production of inflammatory cytokines in the rectal mucosa in patients with septic shock

Conditions: Septic Shock

Summary: life-threatening infection impairs bloodflow to the gut, thereby causing less delivery of oxygen. this leads to increased formation of different inflammatory and infectious markers. the investigators hypothesize, therefore, that there is a significant difference in the concentrations of inflammatory and infectious markers in the rectal mucosa between patients with septic shock and healthy controls.


Eligibility criteria:
inclusion criteria: * septic shock exclusion criteria: * age \< 18 years * no next of kin * pathology of the descending or sigmoid colon or rectum * pregnancy * 1st degree relatives with inflammatory bowel disease * severe coagulopathy
a 12-week study in asthmatic children ages 6 to <12 years, investigating the efficacy and safety of symbicort pmdi 80/2.25 μg and symbicort pmdi 80/4.5 μg, compared with budesonide pmdi 80 μg

Conditions: Asthma

Summary: the purpose is to investigate the efficacy and safety of symbicort pmdi 80/2.25 μg and symbicort pmdi 80/4.5 μg, compared with budesonide pmdi 80 μg, 2 actuations twice daily, in children ages 6 to \<12 years with asthma during 12 weeks.

a phase 3, 12-week, double-blind, randomized, parallel-group, multicenter study investigating the efficacy and safety of symbicort pmdi 80/2.25 μg, 2 actuations twice daily, and symbicort pmdi 80/4.5 μg, 2 actuations twice daily, compared with budesonide pmdi 80 μg, 2 actuations twice daily, in children ages 6 to \<12 years with asthma

Eligibility criteria:
inclusion criteria: * has a documented clinical diagnosis of asthma defined by the ats for at least 6 months prior to visit 2 * have a morning pre-bronchodilator clinic fev1 measured at least 6 hours after the last dose of inhaled saba and at least 48 hours after last dose of inhaled laba of 60% to 100% of predicted normal * demonstrated reversibility of clinic fev1 of ≥12% from pre -albuterol/salbutamol level within 15 to 30 minutes after administration of a standard dose of albuterol/salbutamol. exclusion criteria: * have been hospitalized at least once or required emergency treatment more than once for an asthma-related condition during the 6 months prior to visit 1 * have required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 6 weeks prior to visit 1

Keywords: asthma, children, budesonide pmdi
non-heme iron load quantification in the brain - mri of patients with stroke

Conditions: Stroke

Summary: this study will determine if mri imaging can be used to estimate the amount of iron in areas of the brain affected by a stroke. this may help future patients if the scan can be used to predict the amount of brain damage and therefore the effects on the patient. new research treatments are being used to reduce the amount of iron build-up in the brain. the effects of that treatment may also be estimated using new mri techniques.

hemorrhagic stroke has devastating consequences. the mechanisms resulting in early and delayed brain injury following a hemorrhagic stroke is poorly understood. one of the mechanisms demonstrated in animal studies points towards deposition of iron in the brain tissue following hemorrhage. preliminary data in animal studies also support a favorable effect of iron chelate agents. iron chelate agents are compounds that bind iron to them and may show the extent of neural tissue damage. initial results of human trials based on this hypothesis demonstrated the safety of increasing amounts of desferroxamine given to human patients. the evaluation of iron chelate agents for hemorrhagic stroke is entering into phase ii/iii trials. there is no modality at this date that can quantify the iron in tissue non invasively. some preliminary studies have demonstrated the role of mri in identifying parenchymal iron deposition in traumatic brain injury. we propose to validate an mri based method to not only identify but also quantify the non heme iron levels deposited in brain tissue following hemorrhagic stroke. once validated this method will be a robust mechanism to reliably quantify tissue iron in the brain which then can be closely followed through iron chelate therapy in a trial setting.

Eligibility criteria:
inclusion criteria: 1. males and females between the age of 18 and 85 who have suffered a stroke confirmed by a ct of the head. exclusion criteria: 1. you cannot take part in this study unless you have evidence of having a stroke (hemorrhage in your brain). 2. you cannot take part in this study if you are not able to safely have an mri exam. 3. women cannot take part in this study if they are pregnant. 4. women may not participate in this study if they are attempting to become pregnant or think they might be pregnant. we will provide a one-time pregnancy test for anyone who is uncertain about being pregnant. 5. you cannot take part in this study if you have evidence of a large amount of calcifications found on ct exams that have been performed as part of the clinical evaluation for your current condition.
the development of a screening questionnaire to discriminate autism spectrum disorder and schizotypal disorder, and validation of the danish version of raads-r

Conditions: Autism Spectrum Disorder; Schizotypal Disorder

Summary: the aim of the study is to investigate the validity, reliability and clinical features of a danish version of the ritvo autism asperger diagnostic scale-revised (raads-r). a self-reporting scale devise used as a supplementary questionnaire in diagnosing autism spectrum disorder (asd) in adults. furthermore the validity of novel screening questionnaire: schizotypal autism questionnaire (zaq), will be investigated. zaq is developed to discriminate schizotypal disorder from asd.

the study has 2 parts. part 1: the objective is to develop and validate a self-report screening questionnaire to efficiently discriminate between schizotypal disorder (sd) and autism spectrum disorder (asd) within the adult population. discriminating asd from sd in a clinical setting is a complex and time-consuming task, as they share considerable features both at the symptomatic and the diagnostic criteria. a pilot version of this questionnaire have been developed with 139 questions and named schizotypy autism questionnaire (zaq), to discriminate between these conditions. part 2: raads-r scale, which is a clinical tool that aims to better identify autism spectrum disorders the scale is a self-administered questionnaire completed by the patient himself assisted by a clinician (psychiatrist, psychologist) which ensures the understanding of issues and the choice of answers. the scale contains 80 items including 64 questions describe specific symptoms of autism spectrum disorders and 16 questions to describe non-symptomatic behaviors. the objective of this study is to perform a complete validation of this scale in a danish translation. for both parts of the study 600 adults will be included, 200 adults referred for assessment of autism, 200 adults with another psychiatric disorder, and 200 adults without psychiatric disease.

Eligibility criteria:
inclusion criteria: 1. al patient referred to the outpatient clinic for adhd and autism at pcg, in the research period, for diagnostic assessment of autism spectrum disorder (pervasive developmental disorder, infantile autism, atypical autism and asperger syndrome) 2. wais \> 85, or raven or no-clinical suspicion and education level of 11 years or above 3. completion of 1. clinical assessment 2. adult asperger assessment (aaa) 3. psychopathology evaluation using dsm-v 4. a conclusion based on interdisciplinary consensus exclusion criteria: 1. insufficient danish language skills 2. acute psychiatric illness prompting departure/dismissal from the diagnostic assessment
confocal laser endomicroscopy for in vivo molecular imaging of gastric cancer by targeting mg7-ag

Conditions: Gastric Cancer

Summary: the study aims to: 1. achieve molecular imaging of mg7 antigen in patients with gastric cancer in vivo using confocal laser endomicroscopy. 2. compare the results of in vivo mg7-specific molecular imaging with cle and ex vivo immunohistochemistry .

gastric cancer remains the world's second leading cause of cancer-related death. improved prognosis essentially depend on earlier diagnosis. gastric monoclonal antibody mg7 has been validated as a specific antibody in gastric cancerous tissue. conventional evaluation of mg7 antigen expression is immunohistochemistry, which is time-consuming, and the immunoreactivity can be affected by storage and fixation of tissue. confocal laser endomicrosopy enables visualization of the cellular and subcellular structures in vivo. thus this study aims to achieve molecular imaging of mg7 antigen in gastric cancer in vivo using confocal laser endomicroscopy.

Eligibility criteria:
inclusion criteria: * patients with endoscopically diagnosed gastric cancer exclusion criteria: * patients who are allergic to fluorescein sodium * patients who are unwilling to sign or give the informed consent form * patients with giant tumors or obvious gi tract bleeding which make it hard or impossible to observe the lesions * patients with impaired cardiac, liver or renal function * patients with coagulopathy * patients with pregnancy or breastfeeding
his-pacing and av-node ablation vs. pulmonary vein isolation for atrial fibrillation

Conditions: Atrial Fibrillation; Left Atrial Dilatation

Summary: objective to investigate if conduction system pacing ((csp) i.e. atrioventricular node ablation + his bundle pacing or left bundle branch pacing) is as good as (or better than) atrial fibrillation ablation with pulmonary vein isolation for older patients (70-85yrs) with symptomatic atrial fibrillation and at least moderately dilated left atrium. patient population: 90 patients aged 70-85 years with atrial fibrillation, referred to either av node ablation or pulmonary vein isolation. primary endpoint: improvement in health-related quality of life as measured by the physical component summary (pcs) of the well-validated sf-36 form, at one year after av node ablation + csp or af ablation. secondary endpoints: physical performance measured by 6-minute walk test, biochemical markers of heart failure (nt-probnp), frequency of complications, left ventricular systolic and diastolic function, and left atrial size evaluated after 12 months. arrhythmia specific symptoms and anxiety will be measured with the asta and hads questionnaires. arrhythmia symptom correlation between subjective and objective findings. after three years, clinical endpoints will be evaluated regarding overall survival, and risk of heart failure hospitalization or death. the cost of the treatments will be compared, and estimated cost per quality adjusted year of life will be calculated, based on the eq5d questionnaire.


Eligibility criteria:
inclusion criteria: * indication for invasive treatment of symptomatic atrial fibrillation according to current guidelines * lvef \>35% * age 70-85 years * persistent atrial fibrillation, or paroxysmal atrial fibrillation with at least moderate enlargement of the left atrium (≥42ml/m2) * chronic and well-tolerated treatment with anticoagulants (either non-vitamin k oral anticoagulant or vitamin k antagonist) * willingness to participate, to understand the instructions and fill out the questionnaires, and ability to sign informed consent exclusion criteria: * chronic atrial fibrillation with \>1 year duration * bmi \>40kg/m2 * hypertrophic cardiomyopathy * severe heart failure with symptoms ≥ nyha class iiib * heart amyloidosis * cardiac sarcoidosis * recent (\<3 months) myocardial infarction * significant heart valve disease (pronounced insufficiency or stenosis) * pacemaker or icd treatment ongoing, or current pacemaker indication * congenital heart disease that required surgical correction * comorbidity that is assessed significantly affect the patient's quality of life over the next year, or 3-year survival

Keywords: atrial fibrillation left atrial dilatation pulmonary vein isolation av node ablation conduction system pacing quality of life age group 70 to 85 years
quantification of elastin markers synthesis in williams-beuren syndrome and 7q11.23 micro-duplication syndrome

Conditions: Williams-Beuren Syndrome; Micro-duplication 7q11.23 Syndrome; Vasculopathy

Summary: introduction: williams-beuren syndrome is a rare genetic disorder caused by a 7q11.23 microdeletion. the phenotype associates vasculopathy (arterial stenosis, hypertension), dimorphism and intellectual disability. microdeletion includes several genes: eln encodes for elastin and the haplo-insufficiency (only 1 functional copy) causes vasculopathy. the primary objective is to quantify plasma and urinary levels of elastin peptides in williams-beuren patients and 7q11.23 micro-duplication syndrome patients in order to correlate the levels of these markers with the number of copies of eln gene (proportional positive relationship "gene copy number - circulating levels of markers) materials and methods: this prospective study will be carried out in lyon at the "hôpital femme-mère-enfant" for 2 years. 3 groups of patients will be studied: williams-beuren patients (n=20), micro-duplication 7q11.23 syndrome patients (n=10) and healthy patients (n=60). subjects will be followed for 1 day. clinical examination (weight, height, blood pressure) and biological sample collection (blood and urine sample) will be carry out for williams beuren and micro-duplication 7q11.23 patients group. a large majority of visits will be part of patients' usual care. a large part of patients are systematically seen in consultation once a year. for healthy group, only biological sample collection will be carry out. the pe concentrations will be assessed and compared between the three groups of patients.


Eligibility criteria:
inclusion criteria: * age : from 3 months to 60 years old * williams beuren group : diagnosis confirmed with fish * micro-duplication 7q11.23 group : diagnosis confirmed with cgharray * healthy group : no cardiovascular and neurological medical history * informed consent exclusion criteria: * no social insurance * subject under judicial protection * subject participating in another research including an exclusion period still in progress

Keywords: williams-beuren syndrome micro-duplication 7q11.23 syndrome vasculopathy